Andrew John Armstrong, MD

Professor of Medicine
Associate Professor in Pharmacology and Cancer Biology
Professor in Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-8797
Email address

1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. PI3 kinase/mTOR inhibition in prostate cancer: mechanisms of sensitivity and resistance
7. Developing prognostic models for progression and survival in metastatic prostate cancer
8. Examining surrogate markers of mortality in metastatic prostate cancer
9. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition

In Their Words

Education and Training

  • Fellowship, Division Of Oncology/Hematology, Johns Hopkins University School of Medicine, 2003 - 2006
  • Internship/Residency, General Internal Medicine, University of Pennsylvania School of Medicine, 2000 - 2003
  • M.Sc., Johns Hopkins University, 2008
  • M.D., University of Virginia School of Medicine, 2000
  • B.S.E., Duke University, 1996



Bu, Jiyoon, Ashita Nair, Luke J. Kubiatowicz, Michael J. Poellmann, Woo-Jin Jeong, Marco Reyes-Martinez, Andrew J. Armstrong, et al. “Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical application.” Biosens Bioelectron 162 (August 15, 2020): 112250.

Full Text

Higano, Celestia S., Andrew J. Armstrong, Oliver Sartor, Nicholas J. Vogelzang, Philip W. Kantoff, David G. McLeod, Christopher M. Pieczonka, et al. “Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data.” Cancer 126, no. 12 (June 15, 2020): 2935–37.

Full Text

Stenzl, Arnulf, Curtis Dunshee, Ugo De Giorgi, Boris Alekseev, Taro Iguchi, Russell Z. Szmulewitz, Thomas W. Flaig, et al. “Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study.” Eur Urol, April 23, 2020.

Full Text

Gupta, Santosh, Daniel H. Hovelson, Gabor Kemeny, Susan Halabi, Wen-Chi Foo, Monika Anand, Jason A. Somarelli, et al. “Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.” Genes Chromosomes Cancer 59, no. 4 (April 2020): 225–39.

Full Text

Lu, Changxue, Landon C. Brown, Emmanuel S. Antonarakis, Andrew J. Armstrong, and Jun Luo. “Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations.” Prostate Cancer Prostatic Dis, March 5, 2020.

Full Text

George, Daniel J., Susan Halabi, Patrick Healy, Darius Jonasch, Monika Anand, Julia Rasmussen, Sarah Y. Wood, Charles Spritzer, John F. Madden, and Andrew J. Armstrong. “Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer.” Urol Oncol 38, no. 3 (March 2020): 79.e15-79.e22.

Full Text

Sartor, Oliver, Andrew J. Armstrong, Chiledum Ahaghotu, David G. McLeod, Matthew R. Cooperberg, David F. Penson, Philip W. Kantoff, et al. “Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.” Prostate Cancer Prostatic Dis, February 28, 2020.

Full Text

Freedland, Stephen J., Jenifer Allen, Aubrey Jarman, Taofik Oyekunle, Andrew J. Armstrong, Judd W. Moul, Howard M. Sandler, et al. “A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2).” Clin Cancer Res, February 27, 2020.

Full Text

Marshall, Catherine Handy, Jong Chul Park, Theodore L. DeWeese, Serina King, Michaella Afful, Julia Hurrelbrink, Charlotte Manogue, et al. “Randomized phase II study of sipuleucel-T (SipT) with or without radium-223 (Ra223) in men with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.


Zhang, Tian, Julie Kephart, Elizabeth Bronson, Monika Anand, Christine Daly, Ivan Spasojevic, Hannah Berg, et al. “Disulfiram (DSF) pharmacokinetics (PK) and copper PET imaging in a phase Ib study of intravenous (IV) copper loading with oral DSF for patients with metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.